Residual Cardiovascular Risk Beyond Traditional Factors: Mechanisms, Clinical Significance, and Therapeutic Implications

Abstract

Despite substantial advances in the management of cardiovascular disease (CVD) through targeting traditional risk factors such as hypertension, hyperlipidemia, smoking, and diabetes, a significant proportion of patients continue to experience adverse cardiovascular events. This phenomenon, referred to as residual cardiovascular risk, reflects the complex interplay of non-traditional and emerging risk factors not fully addressed by standard therapies. This review explores the epidemiology, pathophysiology, clinical implications, and current strategies to mitigate residual cardiovascular risk, with a particular focus on mechanisms beyond established risk markers. Recent evidence and guideline updates are discussed to provide a comprehensive, clinically relevant overview for healthcare professionals.

Introduction

Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, despite intensive risk factor modification. While aggressive management of traditional predictors such as dyslipidemia, hypertension, diabetes, and lifestyle factors has significantly reduced CVD incidence, clinical trials and registry data demonstrate a persistent burden of major adverse cardiovascular events (MACE) even among patients achieving guideline-recommended targets. This residual risk underscores the limitations of traditional paradigms and highlights the need for a deeper understanding of underlying mechanisms, novel biomarkers, and innovative therapeutic strategies. For clinicians, addressing this gap is crucial for optimizing long-term outcomes in high-risk populations.

Epidemiology / Disease Burden

Large-scale epidemiological studies, including the Framingham Heart Study and more recent registries, consistently reveal that a considerable proportion of patients with well-controlled traditional risk factors continue to experience myocardial infarction, stroke, or cardiovascular death. For example, in the FOURIER and IMPROVE-IT trials, up to 70-80% of residual events occurred despite intensive statin therapy. The global burden of residual risk is amplified by the growing prevalence of metabolic syndrome, obesity, and aging populations, with significant healthcare and socioeconomic implications. This highlights an urgent need for expanded risk stratification and tailored interventions beyond conventional measures.

Pathophysiology

Residual cardiovascular risk is multifactorial, with contributions from both modifiable and non-modifiable elements not fully addressed by traditional strategies. Key mechanisms include persistent subclinical inflammation, as evidenced by elevated high-sensitivity C-reactive protein (hs-CRP), prothrombotic states, lipoprotein(a) elevation, and residual cholesterol risk related to triglyceride-rich lipoproteins and small dense LDL particles. Genetic predisposition, gut microbiome alterations, and metabolic derangements such as insulin resistance and non-alcoholic fatty liver disease (NAFLD) further contribute to atherogenesis and thrombosis. These insights have shifted the focus toward a systems biology approach for comprehensive risk reduction.

Risk Factors

Beyond established risk factors, several emerging contributors have been identified. Elevated lipoprotein(a) [Lp(a)] is now recognized as an independent, causal risk factor for atherosclerotic CVD. Persistent inflammation, measured by biomarkers such as hs-CRP and interleukin-6 (IL-6), predicts recurrent events even in the absence of hyperlipidemia. Hypertriglyceridemia, particularly in the context of insulin resistance, is gaining recognition as a driver of residual risk. Other contributors include chronic kidney disease (CKD), sleep apnea, psychosocial stress, and subclinical atherosclerosis detected by imaging modalities such as coronary artery calcium scoring or carotid intima-media thickness.

Clinical Features

Patients at risk for residual cardiovascular events often present with features not captured by standard risk calculators. These may include a family history of premature CVD, elevated Lp(a), persistent inflammatory markers, or evidence of plaque progression on imaging despite optimal therapy. Clinical syndromes associated with residual risk include recurrent acute coronary syndromes, heart failure with preserved ejection fraction (HFpEF), and microvascular angina. Recognizing these features is essential for individualizing care and intensifying preventive strategies.

Diagnosis

Identifying residual risk requires a multifaceted approach. Routine assessment of traditional risk factors should be complemented by evaluation of non-traditional markers such as Lp(a), hs-CRP, triglycerides, and renal function. Advanced lipid testing (including measurement of apolipoprotein B and small dense LDL) and genetic screening may be appropriate in selected cases. Non-invasive imaging, including coronary artery calcium (CAC) scoring and carotid ultrasound, can detect subclinical atherosclerosis and stratify risk in intermediate or high-risk individuals. Emerging omics-based biomarkers and risk scores are being developed to further refine risk prediction.

Treatment & Management

Managing residual cardiovascular risk requires a comprehensive, individualized approach. In addition to optimizing statin therapy, consideration of adjunctive lipid-lowering agents such as ezetimibe, PCSK9 inhibitors, and, in specific populations, icosapent ethyl (EPA) for hypertriglyceridemia is warranted. Targeting inflammation with agents such as colchicine or canakinumab has demonstrated benefit in selected populations but is not yet routine. Management of comorbidities such as diabetes, CKD, and sleep apnea remains essential. Lifestyle modification, including dietary optimization, physical activity, smoking cessation, and weight management, continues to play a central role in reducing overall risk.

Recent Advances / Emerging Therapies

Recent years have seen the emergence of novel therapies targeting previously unaddressed mechanisms of residual risk. PCSK9 inhibitors and bempedoic acid offer additional LDL-cholesterol lowering beyond statins. Icosapent ethyl has shown robust reductions in MACE among patients with elevated triglycerides. Antiinflammatory therapies, such as low-dose colchicine and IL-1β inhibitors, have provided proof-of-concept for targeting inflammation in atherothrombosis. Antisense oligonucleotides targeting Lp(a) and RNA-interference therapies are in late-stage development. Advances in precision medicine, including polygenic risk scores and machine learning-based risk assessment, hold promise for individualized patient care.

Guideline Recommendations

Contemporary guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC) now emphasize the importance of comprehensive risk assessment, including evaluation of Lp(a), hs-CRP, and imaging for subclinical atherosclerosis. Adjunctive lipid-lowering therapies are recommended for patients with established CVD and high residual risk. Guidelines also acknowledge the role of anti-inflammatory agents in select patients. Importantly, guideline-directed management highlights the need for a patient-centered, multidisciplinary approach to achieve optimal outcomes.

Conclusion

Residual cardiovascular risk represents a significant challenge in modern preventive cardiology, stemming from multifactorial mechanisms insufficiently addressed by traditional risk factor modification. Recognition of novel risk contributors, improved diagnostic strategies, and the advent of innovative therapies offer new opportunities for risk reduction. Ongoing research and integration of emerging evidence into clinical practice are essential for further decreasing the global burden of CVD and improving long-term patient outcomes.